CN103282024A - 用于纳米聚合物基核酸递送的组合物和方法 - Google Patents

用于纳米聚合物基核酸递送的组合物和方法 Download PDF

Info

Publication number
CN103282024A
CN103282024A CN2011800636609A CN201180063660A CN103282024A CN 103282024 A CN103282024 A CN 103282024A CN 2011800636609 A CN2011800636609 A CN 2011800636609A CN 201180063660 A CN201180063660 A CN 201180063660A CN 103282024 A CN103282024 A CN 103282024A
Authority
CN
China
Prior art keywords
nucleic acid
composition
poly
acetylglucosamine
deacetylated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800636609A
Other languages
English (en)
Chinese (zh)
Inventor
约翰·N·沃纳吉斯
玛丽娜·V·德姆契瓦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Marine Polymer Technologies Inc
Original Assignee
Marine Polymer Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marine Polymer Technologies Inc filed Critical Marine Polymer Technologies Inc
Priority to CN201810672707.5A priority Critical patent/CN108743562A/zh
Publication of CN103282024A publication Critical patent/CN103282024A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CN2011800636609A 2010-11-06 2011-11-07 用于纳米聚合物基核酸递送的组合物和方法 Pending CN103282024A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810672707.5A CN108743562A (zh) 2010-11-06 2011-11-07 用于纳米聚合物基核酸递送的组合物和方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US41086310P 2010-11-06 2010-11-06
US61/410,863 2010-11-06
US41135810P 2010-11-08 2010-11-08
US61/411,358 2010-11-08
PCT/US2011/059558 WO2012061803A2 (en) 2010-11-06 2011-11-07 Compositions and methods for nanopolymer-based nucleic acid delivery

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201810672707.5A Division CN108743562A (zh) 2010-11-06 2011-11-07 用于纳米聚合物基核酸递送的组合物和方法

Publications (1)

Publication Number Publication Date
CN103282024A true CN103282024A (zh) 2013-09-04

Family

ID=46025153

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201810672707.5A Pending CN108743562A (zh) 2010-11-06 2011-11-07 用于纳米聚合物基核酸递送的组合物和方法
CN2011800636609A Pending CN103282024A (zh) 2010-11-06 2011-11-07 用于纳米聚合物基核酸递送的组合物和方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201810672707.5A Pending CN108743562A (zh) 2010-11-06 2011-11-07 用于纳米聚合物基核酸递送的组合物和方法

Country Status (10)

Country Link
US (3) US20130287853A1 (enExample)
EP (1) EP2635261B1 (enExample)
JP (2) JP6029591B2 (enExample)
CN (2) CN108743562A (enExample)
AU (3) AU2011323078B2 (enExample)
CA (1) CA2816999A1 (enExample)
ES (1) ES2763432T3 (enExample)
IL (1) IL226170B (enExample)
MX (1) MX358050B (enExample)
WO (1) WO2012061803A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ599605A (en) 2007-02-19 2013-11-29 Marinepolymer Tech Inc Hemostatic compositions and therapeutic regimens
CN103108638B (zh) 2010-04-15 2016-11-09 海洋聚合物技术公司 聚-n-乙酰葡萄糖胺纳米纤维的抗菌应用
US20130287853A1 (en) * 2010-11-06 2013-10-31 Marine Polymer Technologies, Inc. Compositions and methods for nanopolymer-based nucleic acid delivery
EP3501284A1 (en) 2011-04-15 2019-06-26 Marine Polymer Technologies, Inc. Treatment of skin deseases with poly-n-acetyl glucosamine nanofibers
CA2968160C (en) * 2016-05-31 2024-01-02 Sachiko Sato Use of n-acetylglucosamine and derivatives thereof to treat muscle disorders
EP3693024A1 (en) * 2019-02-05 2020-08-12 Altona Diagnostics GmbH Control for nucleic acid preparation and/or detection methods
IT202200004574A1 (it) * 2022-03-10 2023-09-10 Sergio Ammendola Nanoparticelle di N-acetilglucosammina e loro applicazioni

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100086613A1 (en) * 2008-10-03 2010-04-08 Chang-Jer Wu Chitosan vehicle and method for making same

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
GB0126923D0 (en) * 2001-11-09 2002-01-02 Procter & Gamble Chitosan compositions
US7780873B2 (en) * 2004-02-23 2010-08-24 Texas A&M University System Bioactive complexes compositions and methods of use thereof
JP2005281239A (ja) * 2004-03-30 2005-10-13 Nippon Zeon Co Ltd 鶏用ｄｎａワクチン
US20060105049A1 (en) * 2004-11-12 2006-05-18 Valorisation Recherche Hscm & Universite De Montreal Folic acid-chitosan-DNA nanoparticles
ATE539079T1 (de) 2006-03-23 2012-01-15 Novartis Ag Imidazochinoxalinverbindungen als immunmodulatoren
WO2007109812A2 (en) 2006-03-23 2007-09-27 Novartis Ag Immunopotentiating compounds
EP2068917A2 (en) * 2006-09-22 2009-06-17 Government of the USA, as Represented by the Secretary, Department of Health and Human Services Compositions and methods for chitosan enhanced immune response
KR100882611B1 (ko) * 2006-11-14 2009-02-12 주식회사 키토라이프 표적 리간드로서 폴릭산이 도입된 유전자 전달체용저분자량 수용성 키토산 나노입자 및 이의 제조방법
CA2676919C (en) * 2007-01-31 2013-01-29 Allergan, Inc. Novel biomaterials for ocular drug delivery and a method for making and using same
US20100105139A1 (en) * 2008-10-27 2010-04-29 Remco Alexander Spanjaard Ligand Targeted Nanocapsules for the delivery of RNAi and other Agents
CA2833415A1 (en) * 2010-05-10 2011-11-17 Corporation De L'ecole Polytechnique De Montreal Gene therapy for diabetes with chitosan-delivered plasmid encoding glucagon-like peptide 1
US20130287853A1 (en) * 2010-11-06 2013-10-31 Marine Polymer Technologies, Inc. Compositions and methods for nanopolymer-based nucleic acid delivery

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100086613A1 (en) * 2008-10-03 2010-04-08 Chang-Jer Wu Chitosan vehicle and method for making same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
孙纳等: "壳聚糖脱氧核糖核酸纳米球的制备及其相关特性研究", 《医药导报》 *
王晓波: "《药物运释系统》", 31 August 2007, 中国医药科技出版社 *

Also Published As

Publication number Publication date
EP2635261A2 (en) 2013-09-11
EP2635261A4 (en) 2014-09-17
CN108743562A (zh) 2018-11-06
JP2014500250A (ja) 2014-01-09
MX358050B (es) 2018-08-03
WO2012061803A3 (en) 2012-08-16
EP2635261B1 (en) 2019-10-23
MX2013005016A (es) 2014-03-12
WO2012061803A2 (en) 2012-05-10
AU2011323078A1 (en) 2013-05-02
AU2016201640A1 (en) 2016-04-07
IL226170A0 (en) 2013-07-31
AU2011323078B2 (en) 2016-04-14
JP2016164181A (ja) 2016-09-08
US20230157971A1 (en) 2023-05-25
US20170128382A1 (en) 2017-05-11
US20130287853A1 (en) 2013-10-31
IL226170B (en) 2018-11-29
ES2763432T3 (es) 2020-05-28
JP6029591B2 (ja) 2016-11-24
AU2013203247A1 (en) 2013-05-09
CA2816999A1 (en) 2012-05-10

Similar Documents

Publication Publication Date Title
US20230157971A1 (en) Compositions and methods for nanopolymer-based nucleic acid delivery
US12442005B2 (en) Artificial nucleic acid molecules for improved protein expression
Zhao et al. Enhancing mucosal immune response of Newcastle disease virus DNA vaccine using N-2-hydroxypropyl trimethylammonium chloride chitosan and N, O-carboxymethyl chitosan nanoparticles as delivery carrier
RU2651498C2 (ru) Молекулы искусственной нуклеиновой кислоты
US20250213599A1 (en) Formulation for administration of rna
ES2467678T3 (es) Modificación del ARN, que produce unas estabilidad de transcripción y eficiencia de traducción aumentadas
CN105473158B (zh) 呼吸道合胞病毒(rsv)疫苗
EP3126505B1 (en) Oncolytic vaccinia virus
Běláková et al. DNA vaccines: are they still just a powerful tool for the future?
Zhang et al. Polymers for DNA vaccine delivery
US20120207840A1 (en) Virion Derived Protein Nanoparticles For Delivering Diagnostic Or Therapeutic Agents For The Treatment Of Non-Melanoma Skin Cancer
EP2022853A1 (en) Freeze-dried product for transferring nucleic acid, oligonucleic acid or derivative thereof
AU2017297822A1 (en) Formulation for administration of RNA
Prazeres Plasmid biopharmaceuticals: basics, applications, and manufacturing
US20220145309A1 (en) Yeast-Based Oral Vaccination
Fando et al. DNA vaccine technologies: design and delivery
TW202302141A (zh) 生物可降解的奈米複合疫苗、核糖核酸及去氧核糖核酸疫苗之方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20130904

RJ01 Rejection of invention patent application after publication